PCNA Response: Terisa Trial, ACC.13 Scientific Sessions
Sunday, 10 March 2013 14:51
SAN FRANCISCO, March 10, 2013
The TERISA Trial, presented on Sunday at the American College of Cardiology Scientific Sessions 2013, revealed data that shows the effectiveness of renolazine in reducing angina frequency and SL NTG in patients with type 2 diabetes, CAD and chronic angina.
“This promising data shows beneficial outcomes in type 2 diabetic patients treated with renolazine,” states Barbara Fletcher, RN, MN, FAHA, FPCNA, FAAN from the University of North Florida, Jacksonville and incoming president-elect on the Preventive Cardiovascular Nurses Association (PCNA) board of directors.
“This is important data and gives nurses another medication to use with their patients with elevated HbA1c and chronic stable angina.”
###
Contact: Abby Despins, 920-606-2115, adespins@pcna.net